| Study | Jadad score | Double blind | No. of patients (started/finished) | Final observation period (months) | Cerebral blood flow | Clinical scales | DBS location | Adverse effects* | Patients improved | Patients recovered |
---|---|---|---|---|---|---|---|---|---|---|---|
OCD | Nuttin 1999 [4] | 3 | Yes | 6/4 | 21 | fMRI, PET | POMS | AL/IC | Â | 3 (75%) | Â |
 | Gabriels 2003 [5] | 0 | No | 3/3 | 33-39 |  | BPRS, POMS, Y-BOCS | AL/IC |  | 2 (66%) |  |
 | Nuttin 2003 [6] | 4 | Yes | 6/4 | 21 | fMRI, PET | CGI, Y-BOCS | AL/IC, DMNT |  | 3 (50%) |  |
 | Sturm 2003 [7] | 0 | No | 4/4 | 30-34 | fMRI, PET |  | Right NA |  | 4 (100%) |  |
 | Abelson 2005 [8] | 3 | No | 4/4 | 10 | PET | GAF, HDRS | AL/IC | Mild dizziness | 3 (75%) | 1 (25%) |
 | Greenberg 2006 [9] | 4 | Yes | 10/8 | 36 |  | HDRS, Y-BOCS | AL/IC, VC/C | Seizure, hypomania, relapse with battery failure | 2 (25%) | 4 (50%) |
 | Jimenez 2007** [10] | 0 | Yes | 1/1 |  |  | GAF | ITP |  | 1 (100%) | 1 (100%) |
 | Mallet 2008 [11] | 4 | Yes | 18/168 | 3 |  | GAF, CGI MADRAS, MDRS, MINI, Y-BOCS | STN | 15 major including a brain hemorrhage, 22 minor adverse events | 10 (62%) | 4 (25%) |
 | Nuttin 2008 [12] | 4 | Yes | 6/6 | 21 | PET | CGI, Y-BOCS | AL/IC |  | 3 (75%) |  |
TRD | Jimenez 2005 [13] | 0 | No | 1/1 | 24 | Â | HDRS | ITP | Â | Â | 1 (100%) |
 | Mayberg 2005 [14] | 3 | Yes | 6/6 | 6 | PET | CGI, HDRS, MADRS, PANAS | CG |  |  | 4 (66%) |
 | Schlapfer 2005 [15] | 4 | Yes | 3/3 |  | PET |  |  |  |  | 3 (100%) |
 | Jimenez 2007** [10] | 0 | No | 1/1 |  |  | HDRS, GAS | ITP |  |  | 1 (100%) |
 | Lozano 2008 [16] | 4 | Yes | 20/20 | 12 | PET | BAI, BDI, CGI, HDRS | CG |  | 12 (60%) | 7 (35%) |
 | Malone 2009 [17] | 4 | No | 15/15 | 15 |  | CGI, GAF, HDRS, MADRS | VC/CS |  |  | 6 (40%) |
 | Wang 2009 [18] | 0 | Yes | 21/21*** |  |  | HDRS | STN |  |  |  |
OCD and TRD | Aouizerate 2009 [19] | 0 | Â | 1/1 | 15 | Â | HDRS, Y-BOCS | LCa, NA | Â | 1 (100%) | Â |